These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33907384)

  • 1. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.
    Overton PM; Shalet N; Somers F; Allen JA
    Patient Prefer Adherence; 2021; 15():811-834. PubMed ID: 33907384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis.
    Bril V; Lampe J; Cooper N; Kiessling P; Gardulf A
    J Comp Eff Res; 2024 Sep; 13(9):e230171. PubMed ID: 39115099
    [No Abstract]   [Full Text] [Related]  

  • 3. Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(16):1-86. PubMed ID: 31210833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
    Alten R; An Y; Kim DH; Yoon S; Peyrin-Biroulet L
    Clin Drug Investig; 2022 Jun; 42(6):477-489. PubMed ID: 35657560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.
    McCloskey C; Ortega MT; Nair S; Garcia MJ; Manevy F
    Pharmacoecon Open; 2023 Jan; 7(1):3-36. PubMed ID: 35996066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options.
    Sylwestrzak G; Liu J; Stephenson JJ; Ruggieri AP; DeVries A
    Am Health Drug Benefits; 2014 Apr; 7(2):71-81. PubMed ID: 24991392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE.
    Bell CF; Lau M; Lee M; Poulos C
    Clin Rheumatol; 2021 Feb; 40(2):581-590. PubMed ID: 32623647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.
    Jin JF; Zhu LL; Chen M; Xu HM; Wang HF; Feng XQ; Zhu XP; Zhou Q
    Patient Prefer Adherence; 2015; 9():923-42. PubMed ID: 26170642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence and patient preference for subcutaneous
    Gold R; Schmidt S; Deisenhammer F; Motte J; Richter N; Taipale K; Salmen HC; Bohland C; Schirduan K
    Ther Adv Neurol Disord; 2024; 17():17562864241241382. PubMed ID: 38616781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study.
    van Deen WK; Khalil C; Bonthala NN; Gale R; Patel DB; Warui E; Melmed GY; Spiegel BMR
    Dig Dis; 2023; 41(3):412-421. PubMed ID: 36476714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study.
    Santus P; Ferrando M; Baiardini I; Radovanovic D; Fattori A; Braido F
    World Allergy Organ J; 2019; 12(4):100030. PubMed ID: 31061688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do patients with inflammatory bowel disease want their biological therapy administered?
    Allen PB; Lindsay H; Tham TC
    BMC Gastroenterol; 2010 Jan; 10():1. PubMed ID: 20064220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.
    Stoner KL; Harder H; Fallowfield LJ; Jenkins VA
    Patient; 2014 Jul; ():. PubMed ID: 25015302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review.
    Parra A; Hernández C; Prieto-Pinto L
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1017-1026. PubMed ID: 37665685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.
    Lingman-Framme J; Fasth A
    Drugs; 2013 Aug; 73(12):1307-19. PubMed ID: 23861187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.
    Coates E; Wickramasekera N; Barr A; Shackley P; Lee M; Hind D; Probert C; Sebastian S; Totton N; Blackwell S; Bedford H; Dames N; Lobo A
    Health Technol Assess; 2022 Oct; 26(41):1-118. PubMed ID: 36305390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
    Van den Nest M; Glechner A; Gold M; Gartlehner G
    Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.